← Back to Clinical Trials
Recruiting Phase 4 NCT07523815

NCT07523815 Artificial Intelligence Assisted Workflow Versus Conventional Workflow in Guided Implant Placement

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07523815
Status Recruiting
Phase Phase 4
Sponsor Sandra Moussa Botros El Tarzi
Condition Partially Edentulous Mandible
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-05-01
Primary Completion 2026-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
AI assisted implant placementConventional computer guided implant placement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 20 participants in total. It began in 2026-05-01 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The AI assisted CAD/CAM workflow will be adopted for the treatment planning and guide design generation with the aim of comparing precision of implant placement with conventional digital workflow.

Eligibility Criteria

Inclusion Criteria: * Kennedy class III partially edentulous patient with or without modifications. * Patients who need single implant posterior site delayed implant placement. * Patients above 18 and below 60 years of age. * Natural healthy neighboring teeth without need of new restorations. Exclusion Criteria: * Patients with D4 bone density. * Patients with known systemic or local diseases or treatments which can affect normal tissue healing. * Patients who are heavy smokers. * Presence of signs of active infection or pus formation. * Patients with a need for implants in the anterior region. * Additional oral surgery in the region of interest. * Need For Bone grafting. * Pregnant and/or lactating women

Contact & Investigator

Central Contact

Sandra Moussa El Tarzi, BDS

✉ sandra.eltarzi@dentistry.cu.edu.eg

📞 +201226665141

Frequently Asked Questions

Who can join the NCT07523815 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Partially Edentulous Mandible. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07523815 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07523815 currently recruiting?

Yes, NCT07523815 is actively recruiting participants. Contact the research team at sandra.eltarzi@dentistry.cu.edu.eg for enrollment information.

Where is the NCT07523815 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07523815 clinical trial?

NCT07523815 is sponsored by Sandra Moussa Botros El Tarzi. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology